Edwards Lifesciences (NYSE:EW) PT Raised to $99.00 at Wells Fargo & Company

Edwards Lifesciences (NYSE:EW - Free Report) had its price objective boosted by Wells Fargo & Company from $94.00 to $99.00 in a research note released on Friday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical research company's stock.

Several other brokerages also recently issued reports on EW. OTR Global raised Edwards Lifesciences from a mixed rating to a positive rating in a research note on Tuesday, March 26th. Citigroup increased their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a neutral rating in a research note on Wednesday, April 3rd. Piper Sandler increased their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a research note on Friday. Royal Bank of Canada increased their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an outperform rating in a research note on Monday, April 15th. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an overweight rating in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $93.33.

Edwards Lifesciences Trading Down 1.8 %

Shares of NYSE:EW traded down $1.58 during midday trading on Friday, reaching $86.43. The company had a trading volume of 4,960,142 shares, compared to its average volume of 3,844,076. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a market cap of $52.02 billion, a price-to-earnings ratio of 37.58, a price-to-earnings-growth ratio of 4.39 and a beta of 1.05. The company has a fifty day simple moving average of $90.28 and a two-hundred day simple moving average of $78.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Research analysts predict that Edwards Lifesciences will post 2.76 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company's stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company's stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the sale, the director now directly owns 4,486 shares in the company, valued at approximately $414,596.12. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently modified their holdings of the company. ZWJ Investment Counsel Inc. acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $417,000. First National Trust Co raised its position in Edwards Lifesciences by 17.5% in the 1st quarter. First National Trust Co now owns 4,106 shares of the medical research company's stock valued at $392,000 after purchasing an additional 611 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in Edwards Lifesciences in the 1st quarter valued at $486,000. Patrick M Sweeney & Associates Inc. raised its position in Edwards Lifesciences by 8.0% in the 1st quarter. Patrick M Sweeney & Associates Inc. now owns 3,180 shares of the medical research company's stock valued at $304,000 after purchasing an additional 235 shares during the last quarter. Finally, Verdence Capital Advisors LLC raised its position in Edwards Lifesciences by 7.1% in the 1st quarter. Verdence Capital Advisors LLC now owns 11,599 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 769 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.